Business
Notice of Interim Results Webinar
Notice of Interim Results Webinar.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n 17 June 2022 \n \n \n \n \n \n \n Oxford BioDynamics Plc\n \n \n \n \n (\n \n \n \"\n OBD\n \" or the \"\n Company\n \" and, together with its subsidiaries, the \"\n Group\n \"\n )\n \n \n \n \n \n \n \n \n \n Interim Results Webinar\n \n \n \n Oxford Biodynamics\n Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform , is pleased to announce that the Company's management team will conduct a live presentation via the Yellowstone Advisory webinar platform to investors following their interim results for the half-year ended 31 March 2022, which will be released at 7am on 28 June 2022.\n \n \n The online presentation is open to both existing and potential shareholders. Questions can be submitted both before the presentation by emailing\n \n [email protected]\n \n and during the presentation and will be addressed at the end.\n \n \n The event will take place at 12pm BST on Tuesday 28 June 2022.\n \n \n To register for the presentation, please visit:\n \n https://us02web.zoom.us/webinar/register/1016520892457/WN_HwJq5cd6QTCcL9Tl0FwLrQ\n \n \n \n \n \n \n -Ends-\n \n \n \n \n \n For further details please contact:\n \n \n \n \n \n \n \n \n Oxford BioDynamics Plc\n \n \n \n Jon Burrows, CEO\n \n \n Paul Stockdale, CFO\n \n \n \n \n \n \n \n Tel:\n +44 (0)1865 518910\n \n \n \n \n \n \n \n Shore Capital - Nominated Adviser and Broker\n \n \n \n Advisory: Stephane Auton / John More\n \n \n Broking: Fiona Conroy\n \n \n \n \n \n \n \n Tel:\n +44 (0)20 7408 4090\n \n \n \n \n \n \n \n Instinctif Partners\n \n \n \n Melanie Toyne-Sewell / Jonjo Cordey\n \n \n \n \n Tel: +44 (0)20 7457 2020\n \n [email protected]\n \n \n \n \n \n \n \n \n \n Yellowstone Advisory\n \n \n \n \n \n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n Notes for Editors\n \n \n \n \n \n \n About Oxford BioDynamics Plc\n \n \n \n Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.\n \n \n Its flagship product is \n \n EpiSwitch® CiRT\n \n (Checkpoint Inhibitor Response Test) for cancer, a predictiv...